It’s no surprise that doctors enthuse about the new CGRP class of migraine prevention drugs currently under development. More than 36 million Americans suffer from migraine attacks, and of these, about 4 million have chronic migraine.
Indication: Migraine
Pain
Acurian helps your pain trials succeed, so you can help patients sooner.
Our experience in the wide-ranging spectrum of pain indications, from migraines to osteoarthritis, means you’ll never have to worry about enrollment coming up short.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.
CNS
We’re the nerve center for CNS trials of every type.
Acurian’s extensive trial experience with autism to Alzheimer’s, MDD to Generalized Anxiety Disorder, and other CNS indications, stems from our sensible and sensitive approach to enrolling the patient you need, for as long as you need them.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.